Please assess the completion status of the following clinical trial:

Trial Title: A Study of LY3561774 in Participants With Mixed Dyslipidemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Have fasting triglycerides (TGs) within the range of 150 (1.69 millimole/liter (mmoL) to 499 milligram/deciliter (mg/dL) 2.26 to 5.64 millimole/liter (mmol/L) at screening.~* Have fasting LDL-C ≥70 mg/dL (1.81 mmol/L) at screening.~* Have non-HDL-C ≥ 130 mg/dL (3.36 mmol/L) at screening.~* Must be on a stable moderate or high-intensity dose of a statin for at least 2 months before screening and remain on the same medication and dose for the duration of the study.~* Have a body mass index within the range of 18.5 to 40.0 kilogram/square meter (kg/m²), inclusive~Exclusion Criteria:~* Have in the 6 months prior to screening, uncontrolled Type 1 or Type 2 diabetes, defined as an episode of ketoacidosis or hyperosmolar state requiring hospitalization, or have an hemoglobin A1c (HbA1c) ≥8% at screening.~* Have a history of nephrotic syndrome.~* Have a history of acute or chronic pancreatitis.~* Have had within the past 3 months prior to screening~  * Myocardial infarction~ * Unstable angina~ * Coronary artery bypass graft~ * Percutaneous coronary intervention - diagnostic angiograms are permitted~ * Peripheral artery disease~ * Transient ischemic attack, or~ * Cerebrovascular accident~* Have New York Heart Association Class III or IV heart failure or last known left ventricular ejection fraction \<30%.~* Have undergone LDL apheresis within 12 months prior to screening.~* Have clinically relevant anemia, as defined by the investigator.~* Have, within 1 year prior to screening or plan on having during the study, surgical treatment for obesity.~* Have within 3 years prior to screening a history of chronic alcohol abuse, IV drug abuse, or other illicit drug abuse.~* Have uncontrolled hypertension.~* Have used or are taking products for the purpose of lowering lipid levels (except for statins, PCSK9 inhibitors, bempedoic acid, and ezetimibe). This includes lipid-regulating medication, over-the-counter products, or herbal therapies.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- LY3561774 Dose 1 (Type: EXPERIMENTAL): Participants will receive LY3561774 subcutaneously (SC)
- LY3561774 Dose 2 (Type: EXPERIMENTAL): Participants will receive LY3561774 SC
- LY3561774 Dose 3 (Type: EXPERIMENTAL): Participants will receive LY3561774 SC
- Placebo (Type: PLACEBO_COMPARATOR): Participants will receive placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).